# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001493152-23-012483
Filing Date
2023-04-17
Accepted
2023-04-17 13:45:15
Documents
16
Period of Report
2023-04-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form8-k.htm iXBRL | 8-K | 40898
2 |  | ex99-1.htm | EX-99.1 | 17013
3 |  | ex99-2.htm | EX-99.2 | 929
4 |  | ex99-1_001.jpg | GRAPHIC | 5006
5 | GRAPHIC | ex99-2_001.jpg | GRAPHIC | 578048
| Complete submission text file | 0001493152-23-012483.txt |  | 1042136

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL SCHEMA FILE | anix-20230417.xsd | EX-101.SCH | 3218
7 | XBRL LABEL FILE | anix-20230417_lab.xml | EX-101.LAB | 34240
8 | XBRL PRESENTATION FILE | anix-20230417_pre.xml | EX-101.PRE | 22353
10 | EXTRACTED XBRL INSTANCE DOCUMENT | form8-k_htm.xml | XML | 3621

Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 23823495
SIC: 2834 Pharmaceutical Preparations